This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe
Save the date!
November 6–8, 2023Munich, Germany

Protinhi Therapeutics

Profile

Protinhi Therapeutics is a Dutch biotech preclinical stage scaleup aiming to create a world where effective treatments are available for existing and emerging viral infections. We currently focus on developing antiviral drugs against dengue/broad-spectrum flaviviruses and have additional programs on broad-spectrum coronaviruses and Chikungunya. Our proprietary technology platform employs novel peptidomimetic compounds to inhibit essential viral proteases for virus replication. We have demonstrated in vitro the equivalent high efficacy of compounds inhibiting flaviviruses (~100% for dengue, Zika, West Nile) and coronaviruses (SARS-CoV, SARS-CoV-2 & MERS). The in vivo efficacy of our candidates has also been proven in mouse models to reduce dengue viremia by up to two log units in both therapeutic and prophylactic settings. We are now finalizing the preclinical safety and CTA-enabling studies for the lead dengue program to enter further clinical phase I and II trials.

Novel broad-spectrum antivirals against virus families are an essential -yet missing- tool for outbreak management and for preventing further transmission. Our innovative technology to develop broad-spectrum antivirals has attracted the engagement from multinational pharma companies. Furthermore, Protinhi has a world-class team covering all expertise to develop innovative antiviral compounds to approved antiviral drugs, our in-house expertise includes virology, medicinal chemistry, formulation, and (pre)clinical development. We are committed to deliver our technology for the benefit of viral infectious diseases with a high unmet medical need.

We are now raising a series-A round of Є20M for clinical phase I and II trials on dengue (pan-flavi) and covid (pan-corona) assets. We invite investors and strategic partners to advance the development of our candidates together, further deliver on breakthrough novel antiviral treatment and prepare global society to prevent future epidemics/pandemics.